Thermo Fisher walks away from ASTar distribution deal A blow to confidence in commercial uptake of ASTar Expect material share price drop; estimates under review
Q1 sales in line; FY’22 ASTar placements guidance short We push our placement forecast one year out Long-term unchanged; supported by recent dealmaking
Net sales of SEK 4.3m in-line with our estimates Higher costs drives greater operating loss of SEK-68m Conf. call at 13:00 CEST; commercialisation still in focus